{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:16:58Z","timestamp":1780377418071,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82070227"],"award-info":[{"award-number":["82070227"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-91126-5","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:07:51Z","timestamp":1740377271000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma"],"prefix":"10.1038","volume":"15","author":[{"given":"Yan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Wei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-Fu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Qing","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"91126_CR1","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie, B. G. M. et al. Bortezomib with Lenalidomide and dexamethasone versus Lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open- label, phase 3 trial. Lancet 389, 519\u2013527 (2017).","journal-title":"Lancet"},{"key":"91126_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bjh.15261","volume":"182","author":"EK O\u2019Donnell","year":"2018","unstructured":"O\u2019Donnell, E. K. et al. A phase 2 study of modified Lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br. J. Haematol. 182, 222\u2013230 (2018).","journal-title":"Br. J. Haematol."},{"issue":"1","key":"91126_CR3","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1186\/s12885-022-09980-9","volume":"22","author":"R Medhekar","year":"2022","unstructured":"Medhekar, R., Ran, T., Fu, A. Z., Patel, S. & Kaila, S. Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received bortezomib in combination with Lenalidomide and dexamethasone as first line of therapy in the united States. BMC Cancer. 22 (1), 901\u2013909 (2022).","journal-title":"BMC Cancer"},{"issue":"30","key":"91126_CR4","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A. et al. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J. Clin. Oncol. 33 (30), 3459\u20133466 (2015).","journal-title":"J. Clin. Oncol."},{"key":"91126_CR5","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker, L. et al. Lenalidomide and Dexa methasone in transplant-ineligible patients with myeloma. N Engl. J. Med. 371, 906\u2013917 (2014).","journal-title":"N Engl. J. Med."},{"issue":"26","key":"91126_CR6","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood.2020008787","volume":"137","author":"T Facon","year":"2021","unstructured":"Facon, T. et al. Oral Ixazomib, Lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 137 (26), 3616\u20133628 (2021).","journal-title":"Blood"},{"issue":"10068","key":"91126_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie, B. G. M. et al. Bortezomib with Lenalidomide and dexamethasone versus Lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389 (10068), 519\u2013527 (2017).","journal-title":"Lancet"},{"key":"91126_CR8","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/ajh.22053","volume":"86","author":"SK Kumar","year":"2011","unstructured":"Kumar, S. K. et al. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am. J. Hematol. 86, 640\u2013645 (2011).","journal-title":"Am. J. Hematol."},{"key":"91126_CR9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1182\/blood.V122.21.540.540","volume":"122","author":"C Pawlyn","year":"2013","unstructured":"Pawlyn, C. et al. Lenalidomide combined with cyclophosphamide and dexamethasone is effective and well tolerated induction treatment for newly diagnosed myeloma patients of all ages. Blood 122, 540\u2013540 (2013).","journal-title":"Blood"},{"issue":"8","key":"91126_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41408-018-0106-3","volume":"8","author":"SK Kumar","year":"2018","unstructured":"Kumar, S. K. et al. Phase 1\/2 trial of Ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J. 8 (8), 70\u201379 (2018).","journal-title":"Blood Cancer J."},{"key":"91126_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejca.2018.09.011","volume":"106","author":"MA Dimopoulos","year":"2019","unstructured":"Dimopoulos, M. A. et al. All-oral Ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Eur. J. Cancer. 106, 89\u201398 (2019).","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"91126_CR12","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15 (12), e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"issue":"8","key":"91126_CR13","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17 (8), e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"issue":"22","key":"91126_CR14","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon, T. et al. MAIA trial investigators. Daratumumab plus Lenalidomide and dexamethasone for untreated myeloma. N Engl. J. Med. 380 (22), 2104\u20132115 (2019).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"91126_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41408-024-01024-8","volume":"14","author":"JR Li","year":"2024","unstructured":"Li, J. R. et al. Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing. Blood Cancer J. 14 (1), 38\u201346 (2024).","journal-title":"Blood Cancer J."},{"issue":"13","key":"91126_CR16","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1182\/blood.2022016212","volume":"141","author":"N Stong","year":"2023","unstructured":"Stong, N. et al. The location of the t (4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM. Blood 141 (13), 1574\u20131583 (2023).","journal-title":"Blood"},{"issue":"25","key":"91126_CR17","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1182\/blood-2016-03-706077","volume":"128","author":"YW Qiang","year":"2016","unstructured":"Qiang, Y. W. et al. MAF protein mediates innate resistance to proteasome Inhibition therapy in multiple myeloma. Blood 128 (25), 2919\u20132930 (2016).","journal-title":"Blood"},{"key":"91126_CR18","doi-asserted-by":"crossref","unstructured":"Keats, J. J., Reiman, T., Belch, A. R. & Pilarski, L. M. Ten years and counting: so what do we know about t (4;14) (p16;q32) multiple myeloma. Leuk lymphoma. ;47(11):2289\u20132300. (2006).","DOI":"10.1080\/10428190600822128"},{"issue":"1","key":"91126_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41408-022-00768-5","volume":"13","author":"WJ Chng","year":"2023","unstructured":"Chng, W. J. et al. A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma. Blood Cancer J. 13 (1), 14\u201323 (2023).","journal-title":"Blood Cancer J."},{"issue":"2","key":"91126_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3390\/cancers16020283","volume":"16","author":"A Bors","year":"2024","unstructured":"Bors, A. et al. IGH::NSD2 fusion gene transcript as measurable residual disease marker in multiple myeloma. Cancers (Basel). 16 (2), 283\u2013294 (2024).","journal-title":"Cancers (Basel)"},{"key":"91126_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/leu.2017.204","volume":"32","author":"A Lakshman","year":"2018","unstructured":"Lakshman, A. et al. Natural history of t (11;14) multiple myeloma. Leukemia 32, 131\u2013138 (2018).","journal-title":"Leukemia"},{"key":"91126_CR22","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/gcc.22372","volume":"55","author":"M Leiba","year":"2016","unstructured":"Leiba, M. et al. Translocation t (11;14) in newly diagnosed patients with multiple myeloma: is it always favorable? Genes Chromosomes Cancer. 55, 710\u2013718 (2016).","journal-title":"Genes Chromosomes Cancer"},{"issue":"Supplement 1","key":"91126_CR23","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1182\/blood-2018-99-119051","volume":"132","author":"L Jonathan","year":"2018","unstructured":"Jonathan, L. et al. Outcomes of myeloma patients with t (11;14) receiving Lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy. Blood 132 (Supplement 1), 3282 (2018).","journal-title":"Blood"},{"key":"91126_CR24","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar, S. et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t (11;14) multiple myeloma. Blood 130, 2401\u20132409 (2017).","journal-title":"Blood"},{"key":"91126_CR25","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar, S. K. et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 21, 1630\u20131642 (2020).","journal-title":"Lancet Oncol."},{"key":"91126_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1182\/blood-2020-134847","volume":"136","author":"SK Kumar","year":"2020","unstructured":"Kumar, S. K. et al. Updated analysis of daratumumab plus Lenalidomide and dexamethasone (D-Rd) versus Lenalidomide and dexamethasone (Rd) in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM): the phase 3 MAIA study. Blood 136, 24\u201326 (2020).","journal-title":"Blood"},{"issue":"10192","key":"91126_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau, P. et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 394 (10192), 29\u201338 (2019).","journal-title":"Lancet"},{"issue":"11","key":"91126_CR28","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1001\/jamaoncol.2020.4338","volume":"6","author":"S Giri","year":"2020","unstructured":"Giri, S. et al. Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis. JAMA Oncol. 6 (11), 1759\u20131765 (2020).","journal-title":"JAMA Oncol."},{"issue":"25","key":"91126_CR29","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1200\/JCO.20.03143","volume":"39","author":"CAM Stege","year":"2021","unstructured":"Stege, C. A. M. et al. Ixazomib, daratumumab, and Low-Dose dexamethasone in frail patients with newly diagnosed multiple myeloma: the hovon 143 study. J. Clin. Oncol. 39 (25), 2758\u20132767 (2021).","journal-title":"J. Clin. Oncol."},{"key":"91126_CR30","first-page":"10216","volume":"63","author":"K Groen","year":"2023","unstructured":"Groen, K. et al. Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial. E Clin. Med. 63, 10216\u201310227 (2023).","journal-title":"E Clin. Med."},{"issue":"17","key":"91126_CR31","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1080\/14656566.2018.1528229","volume":"19","author":"PG Richardson","year":"2018","unstructured":"Richardson, P. G. et al. Ixazomib for the treatment of multiple myeloma. Expert Opin. Phgroupacother. 19 (17), 1949\u20131968 (2018).","journal-title":"Expert Opin. Phgroupacother"},{"issue":"9","key":"91126_CR32","doi-asserted-by":"publisher","first-page":"e7177","DOI":"10.1002\/cam4.7177","volume":"13","author":"A Liu","year":"2024","unstructured":"Liu, A. et al. Assessment of prolonged proteasome Inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study. Cancer Med. 13 (9), e7177\u20137186 (2024).","journal-title":"Cancer Med."},{"issue":"24","key":"91126_CR33","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1182\/blood-2017-06-791228","volume":"130","author":"H Avet-Loiseau","year":"2017","unstructured":"Avet-Loiseau, H. et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed\/refractory myeloma patients. Blood 130 (24), 2610\u20132618 (2017).","journal-title":"Blood"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91126-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91126-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91126-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:07:55Z","timestamp":1740377275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91126-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91126"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91126-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Internal Review Board (IRB) of Ruijin Hospital approved this study. Informed consent was obtained from all study participants. The study was carried out following the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6538"}}